MX2018012193A - Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus. - Google Patents

Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.

Info

Publication number
MX2018012193A
MX2018012193A MX2018012193A MX2018012193A MX2018012193A MX 2018012193 A MX2018012193 A MX 2018012193A MX 2018012193 A MX2018012193 A MX 2018012193A MX 2018012193 A MX2018012193 A MX 2018012193A MX 2018012193 A MX2018012193 A MX 2018012193A
Authority
MX
Mexico
Prior art keywords
lenvatinib
everolimus
cell carcinoma
renal cell
treatment
Prior art date
Application number
MX2018012193A
Other languages
English (en)
Inventor
Kremer Alton
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Priority claimed from PCT/JP2017/015461 external-priority patent/WO2017179739A1/en
Publication of MX2018012193A publication Critical patent/MX2018012193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar un carcinoma de células renales con la combinación de lenvatinib o una sal farmacéuticamente aceptable del mismo y everolimus. También se proporcionan dosis y modificaciones de dosis particularmente útiles ante la aparición de eventos adversos.
MX2018012193A 2016-04-15 2017-04-17 Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus. MX2018012193A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016081787 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (en) 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus

Publications (1)

Publication Number Publication Date
MX2018012193A true MX2018012193A (es) 2019-02-11

Family

ID=66213029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012193A MX2018012193A (es) 2016-04-15 2017-04-17 Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.

Country Status (6)

Country Link
US (1) US20190142819A1 (es)
JP (1) JP2019513727A (es)
BR (1) BR112018070526A2 (es)
IL (1) IL262076A (es)
MX (1) MX2018012193A (es)
SG (1) SG10202010137YA (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118119285A (zh) * 2021-10-19 2024-05-31 株式会社大塚制药工场 用于预防或抑制再喂养综合征的组合物

Also Published As

Publication number Publication date
RU2018134943A3 (es) 2020-05-26
BR112018070526A2 (pt) 2019-02-12
IL262076A (en) 2018-11-29
US20190142819A1 (en) 2019-05-16
RU2018134943A (ru) 2020-05-15
SG10202010137YA (en) 2020-11-27
JP2019513727A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2019003938A (es) Compuestos espirociclicos.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MY187540A (en) Compounds active towards bromodomains
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MY201804A (en) Administration and dosage of diaminophenothiazines
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2017012553A (es) Compuestos espirociclicos.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX2017014436A (es) Compuestos biciclicos.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2018012193A (es) Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.
EA201990413A1 (ru) Способ лечения печеночной энцефалопатии
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2019013014A (es) Tratamiento de carcinoma hepatocelular.